Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Mereo BioPharma Group plcNASDAQ: MREO

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital turns positive

Q1 FY2026 change in working capital was $2.16M, compared with -$514K a year earlier. Trailing-twelve-month change in working capital was -$299.66K. Over 3 fiscal years it compounded at +10.9% a year.

Context

  • Change in working capital amounted to 642.1% of revenue in FY2025.
  • Change in working capital grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly change in working capital holds near $2.16M or moves back toward the trailing-twelve-month quarterly average of -$74.91K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.16M+195.9% QoQ
Last fiscal yearDec 2025
-$3.21M+770.0% YoY
LTMMar 2026
-$299.66K-178.4% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+519.7%——
1 year+770.0%——
3-year CAGR+10.9%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(3.21M) USD
Year-over-year change
-770.0%

Change in Working Capital vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -178.4% is the 7th highest of 10, against a peer median of -126.7%.
  • Change in working capital amounts to 59.9% of revenue for MREO, versus a peer median of 149.7%.
MREO Competitors
Change in Working Capital for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$20.45M USD-475.2%——
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$10.9M USD-374.2%+68.3%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€10.48M EUR-2.6%+49.7%78.0%
IMMPImmutep LimitedFY2025A$8.54M AUD-347.1%+76.2%169.4%
SLNSilence Therapeutics plcLTM Mar 2026$5.6M USD——607.2%
ACIUAC Immune S.A.LTM Dec 2025CHF 4.65M CHF-104.3%-8.4%130.0%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$4.29M USD-157.1%-52.9%—
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$1.52M USD-58.9%-24.9%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$1.22M USD-126.7%+14.6%—
CADLCandel Therapeutics, Inc.LTM Mar 2026$447K USD+120.2%+213.8%—
MREOMereo BioPharma Group plcLTM Mar 2026$299.66K USD-178.4%+10.9%59.9%
Peer median (excluding MREO) —-126.7%+32.1%149.7%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income19.22M(42.22M)(29.47M)(43.25M)(41.88M)
Depreciation & Amortization866.47K889K1.06M1.09M622K
Deferred Income Tax00000
Stock-Based Compensation4.46M4.77M4.92M7.39M7.6M
Change in Working Capital(2.49M)(2.35M)(1.59M)(369K)(3.21M)
Accounts Receivables(794.94K)(3.47M)456K(1.65M)1.4M
Inventory00000
Accounts Payables0617K(1.26M)146K(1.38M)
Other Working Capital(1.7M)498K(786K)1.13M(3.23M)
Other Non-Cash Items(29.12M)(9.91M)3.94M2.31M5.9M
Operating Cash Flow(7.07M)(48.82M)(21.13M)(32.83M)(30.97M)
Capital Expenditures(722.06K)(13K)(419K)(699K)(20K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities153.86K2M(419K)00
Investing Cash Flow(568.2K)1.99M(419K)(699K)(20K)
Debt Repayment(933.95K)0(3.19M)00
Common Stock Issued105.99M011.61M47M327.76K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(253.73K)200K24K(853K)(764)
Financing Cash Flow104.8M200K7.97M46.15M327K
Effect of Forex Changes(1.57M)(12.58M)2.82M(233K)1.93M
Net Change in Cash95.59M(59.22M)(10.76M)12.38M(28.81M)
Free Cash Flow(7.79M)(48.83M)(21.55M)(33.53M)(30.99M)

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.